Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Semax spray
Semax spray

Semax spray

Semax for the nose is a native neuroprotective heptapeptide – a synthetic analogue of the ACTH(4-7) fragment, supplied as a reagent kit: a vial with lyophilisate, water for reconstitution and a glass atomizer. Research Use Only reagent

52,99 €
With code BLACK: 42,39 € Lowest price in the 30 days before the discount: 52,99 €

Product unavailable

Notify me when it is back

Leave your e-mail and we will send you one message when the product is available again.

View the laboratory analysis report

Semax nasal – research reagent

  • Semax: native MEHFPGP heptapeptide, ACTH(4-7) fragment analogue.
  • Reagent kit: lyophilisate, water and glass atomizer; not a ready-to-use solution.
  • Research Use Only reagent, not a medicinal product.

Product status information

Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.

Introduction

In the family of neuroprotective peptides derived from the ACTH fragment native Semax is the starting molecule, a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), on which most of the mechanistic work attributed to the entire group has been performed. Semax belongs to the line Endogenic — reagents mapping molecules of endogenous origin or directly derived from them, provided for research on the neuropharmacology of regulatory peptides.

In the Pro-Body catalog it is adjacent to others peptides on brain function used as reference compounds in research on cognitive functions. This reagent provides native Semax as a kit of three elements: a vial with lyophilized native Semax, bacteriostatic water for reconstitution and a glass atomizer with a dosing pump.

This is not a ready-to-use solution: the lyophilisate requires reconstitution with the included water before use in a research protocol. Native Semax is registered in the Russian Federation as a nootropic and neuroprotectant in the form of nasal drops and spray – a fact about that medicine, not a description of how the reagent is used. In preclinical protocols, intranasal administration of neuroprotective peptides is a standard set-up for examining nose-to-brain transport.

In the catalog, the kit belongs to the group peptides spray – reagents supplied with water for reconstitution and an atomizer. The Russian medicine containing Semax was registered in a nasally administered form. The native Semax has a related format in the Pro-Body catalog – only a vial of lyophilisate without water and an atomizer (Semax 50 mg – lyophilized vial) — and the acetylated variant, which should not be confused with it (N-Acetyl Semax Spray – acetylated form).

Unlike the acetylated form, native Semax has a free N-end, which is why it has the shortest half-life – on the order of minutes. The pharmacological profile includes induction of BDNF and NGF in the hippocampus and cortex, central melanocortin profile without corticotropic activity, modulation of dopaminergic and serotonergic transmission, inhibition of enkephalinases and neuroprotection in cerebral ischemia models. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.

REGULATORY STATUS

Native Semax is registered as a medicinal product in the Russian Federation — as a nootropic and neuroprotectant in the form of drops and nasal spray, in indications including ischemic stroke, encephalopathy and optic neuropathy. It is not registered as a medicine in the EU and USA. The Pro-Body kit is a research reagent, not a registered drug – the communication of the product as an “over-the-counter nootropic”, “memory spray” or “neuroprotector for biohackers” is contrary to the Research Use Only framework.

Semax, ACTH fragment and the Russian school of neuroprotective peptides

To understand Semax, you need to go back to the adrenocorticotropic hormone. ACTH is a 39-amino-acid pituitary peptide that stimulates the adrenal cortex to secrete cortisol – its classic hormonal function in the periphery. Already in the 1960s and 1970s, research showed that short fragments of the ACTH molecule, deprived of the part responsible for corticotropic activity, retain a clear effect on the central nervous system – on learning, memory and resistance to stress.

This opened up a separate direction: designing synthetic ACTH fragments as neuropeptides acting in the brain without an adrenal effect. In the 1980s, Ivan Ashmarin’s team at the Institute of Molecular Genetics of the Russian Academy of Sciences (RAN) in Moscow took a fragment of ACTH(4-7) — the Met-Glu-His-Phe sequence — and added the C-terminal tripeptide Pro-Gly-Pro to it.

The heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro was created, called Semax. The addition of proline tripeptide solved a specific problem: it protected the core from immediate degradation and at the same time enhanced the nootropic and neuroprotective profile in behavioral models. Semax was used in research on acute cerebral ischemia and cognitive disorders, and in the Russian Federation it was registered as a nasally administered drug – first in a lower concentration as a nootropic, then in a higher concentration as a neuroprotector in ischemic stroke.

Semax is a textbook example of the Russian school of regulatory peptides: a short sequence designed to separate neurotrophic activity from the hormonal action of the parent molecule. This is the native form of the core to which all subsequent analog work refers. Stabilized derivatives—such as N-Acetyl Semax Spray, in which the N-terminal α-amino group has been blocked with acetyl—modify the pharmacokinetics but inherit the mechanistic core of native Semax.

For this reason, native Semax remains the reference reagent for profile characterization of the entire family and, in the case of this format, the delivered reagent by administration on which its Russian registration is based.

What is Semax?

Semax is a synthetic heptapeptide – an analogue of the ACTH(4-7) fragment (Met-Glu-His-Phe) extended with the C-terminal tripeptide Pro-Gly-Pro. Unlike the acetylated form, it has free chain ends, which is responsible for its short half-life. In this kit, it is supplied as a lyophilized product in a vial along with bacteriostatic water for reconstitution and a glass atomizer.

  • Common name: Semax, native Semax
  • Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (single letter: MEHFPGP); a free α-amino group at the N-terminus (methionine) and a free α-carboxyl group at the C-terminus (proline)
  • Structural origin: an analogue of the ACTH(4-7) fragment (Met-Glu-His-Phe) extended with the C-terminal tripeptide Pro-Gly-Pro; native, unmodified form
  • Chemical class: neuroprotective/nootropic heptapeptide; melanocortin fragment of ACTH without corticotropic activity
  • Supplied form: set – vial with native Semax lyophilisate + bacteriostatic water for reconstitution + glass atomizer; pharmaceutical grade ≥98% HPLC

Table of physicochemical characteristics

Parameter Value Notes
Sequence MEHFPGP (both ends free) heptapeptide, native form
CAS number 80714-61-0 native Semax
Molecular formula C₃₇H₅₁N₉O₁₀S single methionine residue (sulfur)
Molar mass 813.92 g/mol monoisotopic mass verified by MS per batch
Isoelectric point moderately acidic the presence of glutamate and histidine residues; free α-amino group of the N-terminus
Supplied form set: lyophilisate vial + water + glass atomizer for reconstitution of the lyophilisate by the investigator
Purity ≥98% HPLC UV detection, per batch verification
Half-life (model) of the order of minutes (the shortest in the family) free N-terminus susceptible to aminopeptidases

Mechanism of action at the molecular level

Native Semax works through several parallel neurobiological pathways. The following mechanisms have been documented for native Semax in preclinical models – these are the reference data referenced in the descriptions of the stabilized derivatives. Pharmacological profile described for Semax in research models:

  1. Induction of BDNF and NGF expression in the hippocampus and cortex — the best described mechanism. Semax changes the expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the rat hippocampus: a single administration raised BDNF protein at most 1.4-fold and BDNF mRNA (exon III transcript) about threefold; the compound also affects nerve growth factor (NGF) (Dolotov et al. 2006). This is likely the core of its nootropic and neuroprotective profile – increased availability of neurotrophins promotes synaptic plasticity and neuronal survival under conditions of metabolic stress. Importantly, some of the work on neurotrophin induction was performed in animal models of intranasal administration
  2. ACTH(4-7) analogue without corticotropic activity — Semax is derived from a fragment of ACTH, but does not contain the part of the molecule responsible for stimulating the adrenal cortex. In models, it does not stimulate cortisol secretion (no corticotropic effect), maintaining the central melanocortin profile. This distinction is important: neurotrophic and neuroprotective activity is separated from the adrenal hormonal action of parent ACTH
  3. Modulation of dopaminergic and serotonergic transmission — some studies indicate the effect of Semax on the dopamine and serotonin systems in brain structures, which in rodent models correlates with the nootropic and neuroprotective profile (Eremin et al. 2005). The mechanism probably involves modulation of monoamine release and an effect on the expression of genes related to dopamine metabolism
  4. Inhibition of enkephalinases — Semax inhibits the activity of enkephalin-degrading enzymes in serum and tissue, which increases the concentration of endogenous Met- and Leu-enkephalins and prolongs enkephalinergic signaling. This component is a likely contributor to the analgesic and anxiolytic profile observed in the models
  5. Neuroprotection in models of cerebral ischemia — in models of acute ischemia (cerebral artery occlusion in rodents), Semax modulated apoptosis, oxidative stress and the expression of neuroinflammatory and neurotrophic response genes (Medvedeva et al. 2013). This direction was the basis for the registration of Semax as a neuroprotector in ischemic stroke in the Russian Federation

Nose-to-brain mechanism - peptide transport by intranasal administration

Intranasal administration is the dominant route in the preclinical literature on Semax, and the Russian medicine containing Semax was also registered in a nasal form – these are facts about the literature and the drug, not about the intended use of this kit. The molecular logic of transport is well described in peptide neuropharmacology. Most regulatory peptides cross the blood-brain barrier (BBB) ​​poorly when administered peripherally – they are too large and too polar, and the oral bioavailability of the peptide is virtually zero because the gastrointestinal tract degrades the molecule before it can be absorbed.

Intranasal administration offers an alternative delivery route to the central nervous system (CNS), partially bypassing the BBB. Two parallel nose-to-brain transport pathways have been described in research models:

  • Olfactory pathway (olfactory) — a peptide applied to the olfactory epithelium in the upper part of the nasal cavity can be transported along the olfactory nerves directly to the olfactory bulb and further to the structures of the forebrain, bypassing the systemic circulation
  • Trigeminal nerve pathway — the endings of the trigeminal nerve innervating the nasal mucosa constitute a second route of transport to the brain stem and further structures of the CNS

For native Semax, the nasal route is particularly important for two reasons. Firstly, the shortest half-life in the family (of the order of minutes) means that peripheral administration provides a very narrow window of exposure; the intranasal route, partially bypassing first-pass metabolism and the blood-brain barrier, allows the peptide to be delivered closer to central targets before aminopeptidases can cut off the free N-terminus. Secondly, the registration of native Semax in the Russian Federation concerns a nasally administered medicine; that is a fact about the drug, not about the intended use of this reagent.

Important distinction - native Semax vs N-Acetyl Semax spray (and RUO reagent vs Russian drug)

The atomizer kit exists in the Pro-Body catalog in two chemical variants that must not be confused. Both are supplied in the same kit format, but they differ in the modification of the N-terminus of the peptide, and therefore in the proteolytic stability and kinetics of the molecule.

Parameter Native Semax (this kit) N-Acetyl Semax Spray
Sequence MEHFPGP (both ends free) Ac-MEHFPGP (N-acetylation)
Approximate weight 813.92 Da ~855–856 Da
Half-life (model) of the order of minutes (shortest) longer (blocked N-end)
Registration as a medicine yes — native Semax registered in Russia as nasal drops/spray no — a derivative without registration as a medicine
Status of mechanistic data reference molecule, direct data inherited from Semax, require separate validation

IMPORTANT DISTINCTION

Two distinctions are critical here. First – chemical: native Semax (MEHFPGP) is a different molecule than N-Acetyl Semax Spray (Ac-MEHFPGP). Acetylation of the N-terminus in the acetylated variant increases the half-life, but also changes lipophilicity, charge and nasal transport kinetics. Native Semax has the shortest half-life in the family (in the order of minutes), but the clinical data of the registered medicine and all mechanistic data concern this molecule directly, without extrapolation.

Second – regulatory: the registered Russian nasal product and the Semax RUO Pro-Body reagent are not the same. The first is a medicinal product registered in Russia; the second is Research Use Only research material. The identity of the ordered reagent is confirmed only by the sequence and MS mass in the COA of the batch – native Semax is distinguished from the acetylated form by a mass difference of −42 Da (no acetyl group).

Applications in scientific research

The native Semax in this kit is the reference molecule for the entire MEHFPGP family, prepared for the route of administration on which most of the most important work and the Russian registration are based. It is used in research areas:

  • Models of neuroprotection in cerebral ischemia — middle cerebral artery occlusion (MCAO) in rodents; assessment of the effect on infarct size, neuronal apoptosis, oxidative stress and neurotrophic gene expression under acute ischemia
  • Nose-to-brain transport studies — comparative pharmacokinetics of intranasal versus systemic administration for the native form; characterization of the transport kinetics of a peptide with a free N-terminus through the olfactory epithelium and central exposure windows
  • BDNF, NGF and TrkB expression — transcription and protein studies in the cortex and hippocampus after intranasal administration; characterization of the kinetics and strength of neurotrophin induction by native Semax and comparison with stabilized forms
  • Cognitive models — memory and learning tests (Morris water maze, passive avoidance, new object recognition), especially in conditions of cognitive impairment due to stress or hypoxia
  • Melanocortin pharmacology of ACTH fragments — examination of the central activity of the ACTH(4-7) fragment separately from corticotropic activity; profile characterization without adrenal effect
  • Neuroinflammatory models and responses to oxidative stress — assessment of the effect on the cytokine profile and oxidative stress markers in nervous tissue after intranasal administration
  • Monomaminergic and enkephalinergic models — influence on dopaminergic and serotonergic transmission, expression of monoamine metabolism genes and inhibition of enkephalinases in serum and tissue

In studies on central peptides, native Semax is sometimes compared with other regulatory peptides – the reference point for an anxiolytic peptide is, for example, Selank spray (tuftsin analogue, GABA and BDNF axis), also studied in nose-to-brain transport models.

Summary

Semax nasal is a native heptapeptide with the sequence MEHFPGP (both ends free) – a synthetic analogue of the ACTH(4-7) fragment extended with the C-terminal tripeptide Pro-Gly-Pro, developed in the 1980s at the Institute of Molecular Genetics of the RAN in Moscow and supplied as a reagent kit: a vial with lyophilisate, bacteriostatic water for reconstitution and a glass atomizer.

This is the reference molecule of the entire family: most of the mechanistic work referred to in the descriptions of stabilized derivatives – N-Acetyl Semax Spray and Adamax (stabilized Semax analogue). Native Semax has the shortest half-life in the family (in the order of minutes) because the free N-terminus (methionine) is quickly cleaved by aminopeptidases.

The pharmacological profile includes induction of BDNF and NGF in the hippocampus and cortex (in the rat hippocampus, BDNF protein rose at most 1.4-fold), central melanocortin profile without corticotropic activity (does not stimulate the adrenal cortex), modulation of dopaminergic and serotonergic transmission, inhibition of enkephalinases and neuroprotection in models of cerebral ischemia – documented in rodent models, in vitro and in trials carried out in the Russian Federation.

Native Semax is registered as a medicine in Russia in the form of nasal drops/spray; that is a fact about the Russian medicinal product, not about the reagent. HPLC purity ≥98%, MS confirmation (Q-TOF), COA for each batch. Not registered as a medicine in the EU or the USA; the reagent has Research Use Only status.

The broader context of the classification and uses of cognitive-enhancing compounds is discussed in the guide to what they are nootropic substances and when they are the subject of research.

Bibliography

  1. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, et al. (2006). Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. PubMed
  2. Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, et al. (2013). Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain. PubMed
  3. Eremin KO, Kudrin VS, Saransaari P, et al. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. PubMed
  4. Ashmarin IP, Bakaeva ZV, Vas’kovskiy BV, et al. (2003). Highly stable regulatory oligopeptides: experience and applications. PubMed